AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05127330 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LifePlans
Description: LifePlans is a video-based intervention, in which patients watch episodes starting during a psychiatric hospitalization and continuing through 1 month post-discharge. Other mental health treatment is unrestricted.
Study NCT05127330 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Individuals will receive unrestricted routine mental health care in the community as appropriate for their condition.
Study NCT05051475 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic radiofrequency ablation
Description: Endoscopic ablation technique for Barrett's epithelium
Study NCT05051475 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic hybrid argon plasma coagulation
Description: Endoscopic ablation technique for Barrett's epithelium
Study NCT06230133 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBSR intervention
Description: In our study, it is the same to arm description.
Study NCT05457322 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral intervention one
Description: Participants will view or listen to audiovisual material and engage in a daily 10-minute exercise. Following the practice period participants will continue to do the true 28-day intervention period in which they were randomized to.
Study NCT05457322 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral intervention two
Description: Participants will view or listen to audiovisual material and engage in a daily 10-minute exercise. Following the practice period participants will continue to do the true 28-day intervention period in which they were randomized to.
Study NCT05012943 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine
Description: ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine
Study NCT05012943 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (normal saline)
Description: Normal saline with the same volume as of ARCT-154
Study NCT05012943 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Astra Zeneca COVID-19 vaccine
Description: Astra Zeneca COVID-19 vaccine (ChAdOx1 nCoV-19)
Study NCT05257252 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Persons With Disability Friendly Nursing Education Program
Description: Persons With Disability Friendly Nursing Education Program developed based on the Story Theory, 2 weeks program
Study NCT01822951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cerebrolysin
Description: Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). The first treatment course (TC 1) will be in Week 1 and 2, second treatment course (TC 2) will be repeated during Week 9 and 10 and third treatment course (TC 3) during Week 19 and 20.~Placebo for donepezil:1 tablet per day from TC 1 Day 1 on and 2 tablets per day from Visit 3 - Visit 5, p.o.
Study NCT01822951 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Donepezil
Description: 5-10 mg donepezil: 1x5 mg donepezil as 1 tablet per day from TC 1 Day 1 on and 2x5 mg donepezil as 2 tablets from Visit 3- Visit 5, p.o.~Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). The first treatment course (TC 1) will be in Week 1 and 2, second treatment course (TC 2) will be repeated during Week 9 and 10 and third treatment course (TC 3) during Week 19 and 20.
Study NCT05223088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: Participants will receive Tislelizumab, 200mg, intravenously over 30 - 60 minutes, day 1 of every 3 weeks for 3-6 weeks. Discontinuation will be considered due to toxicity, withdrawal of consent, or end of study. Every 3-week treatment period was considered to be a cycle.
Study NCT05223088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib Mesylate
Description: Participants will receive apatinib, 250mg, qd，every 3 weeks for 2-5 weeks.
Study NCT05223088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Participants will receive oxaliplatin, 130mg/m2, day 1 of every 3 weeks for 3-6 weeks.
Study NCT05223088 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tegafur
Description: Participants will receive Tegafur, day 1-14 of every 3 weeks for 3-6 weeks.
Study NCT05792995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sindillimab
Description: Any treatment regimen that includes immunotherapy.
Study NCT06083844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given by IV (vein)
Study NCT06083844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Given by IV (vein)
Study NCT06083844 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given by mouth
Study NCT06308536 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bone powder + collagen membrane
Description: Fill the extraction socket with Bio-Oss® bone powder, and cover the extraction wound with Bio-Gide® collagen membrane.
Study NCT06308536 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone powder + collagen membrane + CGF membrane
Description: Fill the extraction socket with Bio-Oss® bone powder, and cover the extraction wound with Bio-Gide® collagen membrane plus CGF membrane(CGF gel is pressed into a film)
Study NCT06308536 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone powder mixed wih CGF gel + collagen membrane + CGF membrane
Description: Fill the extraction socket with Bio-Oss® bone powder mixed with CGF gel (CGF gel is cutted into granules ), and cover the extraction wound with Bio-Gide® collagen membrane plus CGF membrane(CGF gel is pressed into a film)
Study NCT06308536 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bone powder + CGF membrane
Description: Fill the extraction socket with Bio-Oss® bone powder and cover the extraction wound with CGF membrane(CGF gel is pressed into a film)
Study NCT04993599 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Social robot interaction
Description: The participants interact with the social robot which is controlled by the researcher behind the scene (wizard of oz. method).
Study NCT06233877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-GLIP plus Mitomycin C
Description: G-FLIP: Gemcitabine, Fluorouracil, Leucovorin, Irinotecan, and Oxaliplatin plus Mitomycin C
Study NCT06302023 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Docosahexaenoic acid (DHA) 1000 mg
Description: Pregnant women will be ask to take a DHA 1000 mg per days at bedtime until delivery or 37 week of gestational age
Study NCT06061055 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intubation with VentiBronc Anchor endobronchial double-lumen tube
Description: Patients in this group are intubated with triple-cuffed double-lumen endobronchial tube (VentiBronc Anchor).
Study NCT06061055 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: conventional double-lumen intubation
Description: Patients in this group are intubated with conventional double-lumen endobronchial tube (Shiley).
Study NCT06618053 — intervention group
Intervention type: OTHER
Intervention: cost-effectiveness and audiometry outcomes
Description: Evaluate cost-effectiveness of stapes surgery performed under local anesthesia as well as evaluate audiometry outcomes
Study NCT06425666 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intervention group /arm 1 (Cataract surgery alone)
Description: Cataract surgery (arm 1) is performed using a small incision technique. The tunnel is used both for cataract surgery and for implantation of the DMEK graft (arm 2). The centres confirmed that the main incision will be localized between 11 and 12 o'clock and will have a width of 2.4 to 2.8 mm. A tunnel suture will only be placed if there is leakage from the incisions. If cataract surgery alone (arm 1) is performed, a thin dispersive viscoelastic is applied to the endothelium for protection before phacoemulsification. A hydrophobic acrylic monofocal IOL will be implanted into the bag. The centers confirmed that Barret Universal II formula is the standard IOL calculation formula for both groups and for all axial lengths.
Study NCT06425666 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Control group /arm 2: Corneal transplantation as Descemet Membrane Endothelial Keratoplasty (DMEK) in combination with cataract surgery (triple-DMEK)
Description: After cataract surgery DMEK is continued using the surgeon's standard technique for graft implantation and unfolding in triple-DMEK. In all cases the graft will be implanted using the same main incision as for IOL implantation. Once the DMEK graft is unrolled and attached to the posterior corneal stroma the complete anterior chamber will be filled with SF6 20%.
Study NCT05161078 — intervention group
Intervention type: DEVICE
Intervention: CARPEDIEM
Description: CARPEDIEM treatment as per local standard of care
Study NCT05228886 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SINCERE
Description: Each goal setting session will involve templated prompts in 211's ServicePoint to guide the creation of a patient-centered action plan specifying what, when, how much, and how often patients will engage in a behavior (e.g., I will work on filling out eligibility paperwork for 30 minutes on Wednesday evening). Again, following clear prompts, ISs negotiate the action plan with patients until patients can rate their level of confidence for achieving this behavior a 7 on a scale from 0 to 10.
Study NCT05228886 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Scheduled Follow-Up
Description: Adding to the standard Call + Resources protocol, those assigned to scheduled follow-up will receive a proactive call from 211 every 2 weeks for 3 months to explore additional service needs. These calls will be unstructured, guided by participant requests and 211 IS prompts.
Study NCT05228886 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: 211 ISs contact referred patients, provide referral services, and follow up in an ad-hoc manner.
Study NCT04747990 — intervention group
Intervention type: PROCEDURE
Intervention: Early Definitive Treatment
Description: defined as treatment in accordance with the current guidelines (cholecystectomy or ERCP with endoscopic sphincterotomy during the same hospital admission or within 2 weeks of discharge)
Study NCT05011916 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KDR2-2 suspension eye drops
Description: All patients were instructed to instill one drop four times per day in the study eye for 6 weeks.
Study NCT05315830 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER2 Tumor Vaccine
Description: B-cell epitope vaccine HER2 Tumor Vaccine 0.6 μg，Intramuscular injection on D1, D14 and D28
Study NCT05315830 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER2 Tumor Vaccine+ Standard of Care chemotherapy
Description: B-cell epitope vaccine HER2 Tumor Vaccine 0.6 μg，Intramuscular injection on D1, D14 and D28 Standard of Care Chemotherapy cisplatin by intravenous administration at 80 mg/m2 on the first day of each cycle and either 5-FU, 4000 mg/m2 CIV (administered as 1000 mg/m2/day as continuous infusion for 96 hours on days 1 to 4 of each cycle) or capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 1 to 14 of each cycle) or other standard of care chemotherapy
Study NCT06255093 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Community-based recreation program referral
Description: Provide referral to local Parks and Recreation for programs of interest and participation. Participants will have the option to join a program (up to 4months) and have access to additional resources via study webpage to identify support services.
Study NCT06255093 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Pre-surveys only
Description: Receive online wellness education and anxiety treatment options information
Study NCT04360083 — intervention group
Intervention type: OTHER
Intervention: Collected data from Rhône RéPPOP database
Description: BMI Z-scores at the start and the end of RéPPOP care programs.
Study NCT04360083 — intervention group
Intervention type: OTHER
Intervention: telephonic questionnaire
Description: Collected data though the telephonic questionnaire : current declared BMI Z-score.
Study NCT05132530 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: yoga
Description: yoga practice will be done two days a week for 10 weeks.
Study NCT05124821 — intervention group
Intervention type: DEVICE
Intervention: Central venous catheter intended to be used for children during routine clinical practice
Description: Device will applied according to instruction for use (IFU) and respective indication during routine clinical practice.
Study NCT05995405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GTX-104
Description: Nimodipine IV infusion
Study NCT05995405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nimotop 30 MG Oral Capsule
Description: Oral nimodipine capsules
Study NCT05497232 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: simultaneous pancreas-kidney transplantation
Description: Renal transplants were performed to the right external iliac artery and vein, and the ureter was anastomosed to the recipient ureter by using end-to-end anastomoses techniques. All the renal allografts were placed into retroperitoneum.~Enteric drainage of exocrine secretions was performed on all pancreas transplants, systemic venous outflow (postcava), and arterial reconstruction with y graft (iliac artery). Lastly in all cases of renal transplant, the artery was anastomosed in all cases. The pancreas was placed intra-abdominally in all cases.
Study NCT04189133 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutropin alfa
Description: daily increasing dosages of lutropin alfa
Study NCT04189133 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human chorionic gonadotropin
Description: human chorionic gonadotropin increasing administration
Study NCT05150782 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin/Boswellia Serrata/Ascorbic acid mixture
Description: The daily intake of 2x10 drops of a mixture of micellized curcumin (2%), boswellia serrata (1.5%) and ascorbic acid (6%).
Study NCT05559424 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: OCT
Description: OCT will be used to assess results after intervention
Study NCT05959161 — intervention group
Intervention type: PROCEDURE
Intervention: DBS
Description: We observed the prognostic changes of patients after DBS surgery
Study NCT05459025 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aromatherapy yoga
Description: The research assistant diluted the Lavandula angustifolia essential oil with distilled water (1:75) 10 min before the yoga session started. The solution was then atomized by three aroma diffusers, placed in the front, middle, and back of the classroom. The distance from each participant was less than 10 m to ensure that the aroma was absorbed com-pletely. The yoga course for the aromatherapy yoga group was the same as that of the yoga only group. The yoga group only took a yoga course, without aromatherapy.
Study NCT05459025 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga
Description: The design of the yoga lessons was based on a past study and a professional yoga instruction book. Yoga lessons were led by certified yoga tutors.
Study NCT04849533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept
Description: belatacept with everolimus is experimental regimen and it is compared to the labeled regimen of belatacept with mycophenolate with steroids for prevention of rejection in renal transplant recipients
Study NCT04849533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Belatacept
Description: belatacept with everolimus is experimental regimen and it is compared to the labeled regimen of belatacept with mycophenolate with steroids for prevention of rejection in renal transplant recipients
Study NCT04849533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: belatacept with everolimus is experimental regimen and it is compared to the labeled regimen of belatacept with mycophenolate with steroids for prevention of rejection in renal transplant recipients
Study NCT04849533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: belatacept with mycophenolate is approved regimen for prevention of rejection
Study NCT05169814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micro/nanobubble (MNB) - Irrigation
Description: An MNB solution will be used as an irrigation solution to improve wound oxygenation in ischemic tissue (e.g. ischemic surgical tissue, traumatic wounds, and failing replants). The MNB solution will be used in wet-to-dry wound care dressings with daily scheduled dressing changes.
Study NCT05169814 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal Saline - Irrigation
Description: A normal saline solution will be used as an irrigation solution to improve wound oxygenation in ischemic tissue (e.g. ischemic surgical tissue, traumatic wounds, and failing replants). The normal saline solution will be used in wet-to-dry wound care dressings with daily scheduled dressing changes.
Study NCT05169814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Micro/nanobubble (MNB) - Negative Pressure Wound Therapy with Instillation (NPWTi)
Description: NPWTi with MNB will be applied to the wound with 20-minute instillation periods every 3 hours (standard instillation settings) with dressing changes every 3-5 days.
Study NCT05169814 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Normal Saline - Negative Pressure Wound Therapy with Instillation (NPWTi)
Description: NPWTi with normal saline will be applied to the wound with 20-minute instillation periods every 3 hours (standard instillation settings) with dressing changes every 3-5 days.
Study NCT06646653 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alma System
Description: Subjects diagnosed with postpartum hemorrhage will receive the Alma System. This system comprises a soft silicone cylindrical device placed within the uterus. Gentle suction is applied, prompting the uterus to contract and reduce in size. This contraction compresses the blood vessels, halting the bleeding.
Study NCT05680285 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: diode lazer
Description: diode laser was applied during the pulpotomy procedure
Study NCT05680285 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: low level diode laser
Description: Low-dose diode laser was applied during the pulpotomy procedure
Study NCT05139498 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conservative management for placenta accreta spectrum (PAS)
Description: Subjects who are randomized to to conservative management will undergo a cesarean delivery followed by a period of close observation in the operating room for 30-45 minutes to be sure there is no excessive bleeding or risk to keep the placenta inside
Study NCT05139498 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean hysterectomy for placenta accreta spectrum (PAS)
Description: Subjects who are randomized to cesarean hysterectomy will undergo a cesarean delivery followed immediately by hysterectomy to remove the placenta and uterus together
Study NCT04849533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: corticosteroids
Description: belatacept with chronic steroids is approved regimen for prevention of rejection
Study NCT05910697 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MyProstateScore 2.0 Results
Description: Being shown the results of a diagnostic test for the likelihood of finding clinically significant cancer from a prostate biopsy and how it changes clinical practice.
Study NCT04666376 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: evaluation of the effectiveness of vitrification technique on ovarian tissue quality
Description: there are 3 types of experiments in each group, including Follicle survival evaluation by Neutral red staining, Histological evaluation by Hematoxylin and Eosin staining, 2.4. Evaluation GDF-9 and Caspase-3 gene expression by real-time PCR.
Study NCT04849533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rabbit antithymocyte globulin
Description: rabbit antithymocyte globulin induction for prevention of rejection
Study NCT04849533 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rabbit antithymocyte globulin
Description: rabbit antithymocyte globulin induction for prevention of rejection
Study NCT05304494 — intervention group
Intervention type: OTHER
Intervention: Biomarker tests for participant profiling
Description: Combination of digital and physical tests to objectify measures relevant for breathlessness
Study NCT04887701 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-hormonal vaginal device therapy
Description: Experimental Active Therapy
Study NCT04887701 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham vaginal device therapy
Description: Sham Comparator
Study NCT01308047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: single dose of 15mg by a slow injection rate of 1 ml/s
Study NCT01308047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: single dose of 15mg by a slow injection rate of 1 ml/s